The University of Queensland

Xenome Limited

The University of Sydney

Richard James Lewis

Paul Francis Alewood

Iain Andrew Sharpe

Dianne Alewood

Elka Palant

Katherine Justine Nielsen

David John Adams

Iain A Sharp

Jennifer Deuis

Geza Berecki

Roger Drinkwater

Roger Desmond Drinkwater

Zoltan Dekan

Irina Vetter

MacDonald James Christie

This invention relates to peptides and their use for modulating sodium channels. More particularly, the present invention relates to peptides from the venom of the tarantulaand their use in methods of inhibiting Na1.7 and for treating or preventing conditions associated with Na1.7 activity such as neuropathic, inflammatory and nociceptive pain.

Spider venom peptides and methods of use for modulating sodium channels

This invention relates to an isolated, synthetic or recombinant peptide, wherein the peptide comprises the sequence: C K G K G A XaaC R XaaXaaXaaY XaaC C XaaG XaaC R XaaXaaR C SEQ ID NO: 1 wherein Xaa, Xaa, Xaa, Xaa, Xaaand Xaaare independently selected from serine and threonine; Xaais selected from arginine and lysine; Xaais selected from aspartic acid and glutamic acid; and Xaais selected from glycine, alanine, valine, leucine and isoleucine.

Omega conotoxin peptides

The present invention relates generally to methods for inducing, promoting or otherwise facilitating pain relief. More particularly, the present invention relates to a synergistic combination of a selective inhibitor of the neuronal norepinephrine transporter and an analgesic agent in the therapeutic management of vertebrate animals, including humans, for producing analgesia or for the prevention or alleviation of pain.

Combination therapy

The invention relates to an isolated, synthetic or recombinant &#x3c7;-conotoxin peptide having the ability to inhibit a neuronal amine transporter, nucleic acid molecules encoding all or part of such peptides, antibodies to such peptides and uses and methods of treatment involving them.

Conotoxin peptides useful as inhibitors of neuronal amine transporters

An isolated, synthetic or recombinant &#x3c7;-conotoxin peptide comprising the following sequence of amino acids: Xaa1 Xaa2 Gly Val Cys Cys Gly Tyr Lys Leu Cys His Pro Cys SEQ ID NO. 3 where Xaa1 is a N-terminal Xaa1 is a N-terminal pyroglutamate (pGlu) or D-pyroglutamate (DpGlu) residue; and Xaa2 is Asn or a deletion; or such a sequence in which one or more Cys is replaced with its corresponding D-amino acid and/or one or more amino acid residues other than Cys has undergone a side chain modification, or a salt, ester, amide or prodrug thereof. The invention also relates to pharmaceutical compositions comprising these peptides and the use of these peptides in the prophylaxis or treatment of conditions, such as but not limited to, pain, inflammation, incontinence, cardiovascular conditions and mood disorders.

&#x3c7;-conotoxin peptides (-1)

An isolated, synthetic or recombinant X-conotoxin peptide having the ability to inhibit neuronal amine transporter comprising the following sequence of amino acids: Cys Cys Gly Tyr Lys Leu Cys Xaa5 Xaa6 Cys, SEQ ID NO:3, where Xaa5 and Xaa6 are independently absent or represent any amino acid residue except Cys; or a sequence in which Gly, Tyr, Lys or Leu are subject to conservative amino acid substitution or side chain modification with the proviso that the peptide is not MrIA, MrIB, Mar2, CMrVIA, Bn1.5, Mr1.3 or Au1.4; or a salt, ester, amide, prodrug or cyclised derivative thereof.

Type II chi-conotoxin peptides (noradrenaline transporter inhibitors)

Conotoxin peptides

An isolated, synthetic, or recombinant &#x3c9;-conotoxin peptide in which the fourth loop between cysteine residues 5 and 6 comprises SEQ ID NO: 1 or such a sequence which has undergone one or more amino acid substitutions or side chain modifications, and uses therefor. SEQ ID NO: 1 comprises the amino acid sequence SGTVGR.

&#x3c9;conotoxin peptides

The present invention relates to novel peptides and derivatives thereof useful as selective &#x3b1;-adrenoceptor antagonists which ability of inhibiting the agonist action of agonist noradrenaline on the &#x3b1;-adrenoceptor is greater than their ability of inhibiting the action of agonist noradrenaline on the other &#x3b1;-adrenoceptors. The invention also relates to pharmaceutical compositions comprising these peptides.

Peptides

The invention relates to an isolated, synthetic or recombinant &khgr;-conotoxin peptide having the ability to inhibit a neuronal amine transporter, nucleic acid molecules encoding all or part of such peptides, antibodies to such peptides and uses and methods of treatment involving them.

Growing community of inventors

Woolloongabba, Australia

Richard James Lewis